The story of Sildenafil presents a complex picture for shareholders. While the initial launch generated significant gains, the lapse of its patent opened the floodgates to generic alternatives, dramatically reducing https://social4geek.com/story7340120/the-copyright-and-pharma-a-volatile-bet